One of the more recent studies is the Olympya trial, where patients with HER2-negative early breast cancer and germline PVs or LPVs in FANCD1/BRCA2 and FANCS/BRCA1 are treated with adjuvant Olaparib (312). Here, BRCA2 is linked to breast cancer.